Motion-onset VEPs to translating,radial, rotating and spiral stimuli

Motion-onset related visual evoked potentials (M-VEPs) were recorded as a result of the three basic (translating, radial and rotating) and one complex (spiral) motion stimulations in five subjects. Low contrast, retinotopically scaled patterns evoked potentials with major motion-onset specific negativity N160 with maximum in the parieto-temporal region. All multidirectional motion stimuli elicited the motion-onset response of significantly higher amplitude and shorter latency compared to the translating (unidirectional) motion. The rotation-onset evoked potentials had significantly shorter latencies than the rest of explored stimuli. The most stable responses with the largest N160 amplitude were recorded to the radial motion. After masking of the central 20° of the visual field these motion-onset VEPs were acquired without statistically significant amplitude drop. The efficiency and usefulness of the radial stimulus is presented in two clinical cases.     

阿里红中总三萜酸的提取工艺优选及含量测定

目的:优化阿里红中总三萜酸的提取工艺,并建立其含量测定方法。方法:以齐墩果酸为对照品,采用分光光度法测定三萜酸含量;采用单因素试验考察提取溶剂种类及浓度、料液比、温度、提取时间及提取次数对总三萜酸得率的影响,在此基础上,采用L9(34)正交试验优选阿里红中总三萜酸提取工艺。结果:最佳提取工艺为30倍量90%乙醇于60℃超声提取3次,每次30 min。在此条件下,阿里红中总三萜酸质量分数35.1%。各因素影响次序为提取温度>液料比>提取时间>乙醇体积分数。结论:阿里红中三萜酸含量很高,该优选工艺稳定可行,可推广于大生产。     

基于高频药对及功效配伍数据分析探讨治疗冠心病的组方规律

目的:应用高频药对和功效配伍关系等数据挖掘技术分析治疗冠心病的维吾尔医古籍方剂配伍组方特点,揭示内在规律,探索配伍组方理论,指导临床合理用药,为新药研发提供方剂线索。方法:以历代医家古方为线索,借助于现代数据处理与统计的计算机技术,建立冠心病方剂的Microsoft Excel数据库,通过高级筛选功能,对高频药对和功效配伍进行统计分析。结果:通过数据挖掘与分析,发现已知和未知的增效、减毒的药品组合,其中高频药对为牛舌草-香青兰,牛舌草-蚕茧-玫瑰花瓣,牛舌草-檀香;高频3味药组为牛舌草-香青兰-蚕茧,牛舌草-香青兰-檀香/玫瑰花,牛舌草-蚕茧-檀香;高频4味药组为:牛舌草-香青兰-蚕茧-檀香,牛舌草-香青兰-琥珀-麝香;高频,5味药组为蚕茧-珍珠-琥珀-麝香-大叶补血草-矢车菊,牛舌草-香青兰-蚕茧/珍珠-大叶补血草-矢车菊,探究功效配伍的最佳组合。结论:以强心药为主药,配伍补脑药、增强自然力药、强筋药、补肾药、健胃顺肠药以及致病异常体液相应成熟药是组方规律,基本方以蚕茧、檀香、珍珠、麝香、琥珀、大叶补血草、矢车菊、银箔、金箔、西红花、牛舌草、香青兰、丁香、郁金、多榔菊、天竺黄为构成,为此推论为临床遣药用药和新药研发提供参考依据。     

Levosimendan may improve survival in patients requiring mechanical assist devices for post-cardiotomy heart failure

Introduction  

Most case series suggest that less than half of the patients receiving a mechanical cardiac assist device as a bridge to recovery due to severe post-cardiotomy heart failure survive to hospital discharge. Levosimendan is the only inotropic substance known to improve medium term survival in patients suffering from severe heart failure.     

Review on clinical trials of targeted treatments in malignant mesothelioma

Purpose  

Malignant mesothelioma (MM) is an aggressive tumor of the serosal surfaces with a poor prognosis. Advances in the understanding of tumor biology have led to the development of several targeted treatments, which have been evaluated in clinical trials. This article is a comprehensive review of all clinical trials evaluating the effect of targeted treatments in MM.